This study focuses on patients with advanced hepatocellular carcinoma, which is a type of liver cancer that has spread or cannot be removed by surgery. The research evaluates several medications including rilvegostomig, bevacizumab, and tremelimumab, which are drugs that work with the immune system to fight cancer cells. Another medication being studied is atezolizumab, which also helps the immune system target cancer cells.
The main purpose of this research is to determine if combining rilvegostomig with tremelimumab and bevacizumab is more effective than using atezolizumab with bevacizumab in treating advanced hepatocellular carcinoma. These medications are given through intravenous infusion, which means they are delivered directly into the bloodstream through a vein.
During the study, patients will be randomly assigned to different treatment groups. One group will receive rilvegostomig together with tremelimumab and bevacizumab, while another group will receive atezolizumab with bevacizumab. The study will monitor how patients respond to these treatments over time, particularly focusing on how long patients survive after starting treatment.
France 
Germany 
Italy 
Poland 
Spain 
The Netherlands 
